G01N 2800/085
Liver diseases
Official title: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
G01N2800/085 (Liver diseases) appears on 309 US grants and 716 published applications in this corpus.
Search patents in G01N- Granted patents
- 309
- Published applications
- 716
- Assignees
- 418
- Inventors
- 1,449
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 1 | 3 |
| 2004 | 1 | 7 |
| 2005 | 0 | 7 |
| 2006 | 2 | 9 |
| 2007 | 4 | 18 |
| 2008 | 3 | 15 |
| 2009 | 3 | 20 |
| 2010 | 8 | 26 |
| 2011 | 6 | 27 |
| 2012 | 10 | 20 |
| 2013 | 14 | 22 |
| 2014 | 13 | 38 |
| 2015 | 13 | 33 |
| 2016 | 10 | 39 |
| 2017 | 28 | 30 |
| 2018 | 28 | 46 |
| 2019 | 30 | 43 |
| 2020 | 27 | 62 |
| 2021 | 21 | 38 |
| 2022 | 15 | 46 |
| 2023 | 18 | 49 |
| 2024 | 19 | 50 |
| 2025 | 22 | 40 |
| 2026 | 12 | 26 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of autoimmune liver disease15 Sep 2026US 12,736,544 B2The Governors of the University of Alberta
- Method for NASH risk assessment26 May 2026US 12,638,460 B2Genfit
- Compositions for diagnosis, prevention, or treatment of fatty liver disease19 May 2026US 12,630,879 B2Hysensbio
- Personalized liver cancer treatment5 May 2026US 12,620,468 B2
- Methods for treating cholestasis14 Apr 2026US 12,599,602 B2Mirum Pharmaceuticals, Inc.
- Method for evaluating onset risk of non-alcoholic fatty liver disease, and biomarkers8 Oct 2026US 2026/0309702 A1Shimadzu Corporation
- Methods for treating cholestasis1 Oct 2026US 2026/0294903 A1Mirum Pharmaceutical, Inc.
- Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications24 Sep 2026US 2026/0287589 A1Board of Regents, The University of Texas System
- Methods for treating cholestasis10 Sep 2026US 2026/0263458 A1Mirum Pharmaceuticals, Inc.
- Methods for diagnosing advanced liver fibrosis or liver cirrhosis10 Sep 2026US 2026/0266842 A1Genfit
Most cited
By later US patents
- Human FGF-21 nucleic acids138US 6,716,626 B1Chiron Corporation · 2004
- Human FGF-21 polypeptides95US 7,259,248 B2Chiron Corporation · 2007
- Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-193US 7,598,228 B2Asubio Pharma Co., Ltd. · 2009
- Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers46US 6,631,330 B1Assistance Publique-Hopitaux De Paris (Ap-HP) · 2003
- Human FGF-21 gene and gene expression products35US 7,723,297 B2Kyoto University · 2010